Novartis Pharmaceuticals Corporation v. Roxane Laboratories Inc., No. 08-CV-3853; U.S. District Court (DNJ); opinion by Cavanaugh, U.S.D.J.; filed March 31, 2011. DDS No. 53-7-1601 [24 pp.]
Plaintiffs Novartis International Pharmaceutical Ltd., Novartis Pharmaceutical Corporation, and Novartis Pharma, AG (Novartis) market and sell the drug Famvir in the United States for the treatment of various herpes-related infections. The active antiviral agent in Famvir is the chemical compound famciclovir. Novartis’s patent in this suit, U.S. Patent No. 5,246,937 (the ’937 patent), claims the compound famciclovir and its use for treating viral infections.
